Mepolizumab in the treatment of severe asthma with nasal polyposis: real-life study Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021
Rhinitis, nasosinusal polyposis and asthma: clinical aspects Source: ISSN=1025-448x, ISBN=1-904097-19-17, page=101 Year: 2001
Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
Dupilumab improves mental health measures in patients with chronic rhinosinusitis and nasal polyposis (CRSwNP) Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018
Incidence of nasal polyposis and its association with the development of chronic bronchitis and/or emphysema Source: Eur Respir J 2002; 20: Suppl. 38, 401s Year: 2002
Nonallergic rhinitis, sinonasal polyposis and asthma Source: Eur Respir J 2003; 22: Suppl. 45, 108s Year: 2003
Comorbidities, hypersensitivity and biomarkers in a real-world US nasal polyps population Source: International Congress 2019 – Asthma and the world Year: 2019
Real-world evidence of reported symptoms and quality of life burden associated with chronic rhinosinusitis with nasal polyposis and comorbid asthma status Source: Virtual Congress 2021 – Patient-reported outcome measures (PROMs): easy tools in the management of chronic respiratory diseases Year: 2021
Mepolizumab reduces nasal symptoms in asthmatic patients with chronic rhino-sinusitis and nasal polyposis: a 12 months real-life study Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020
Dupilumab reduces blood and nasal biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps with and without comorbid asthma: SINUS-52 trial Source: Virtual Congress 2020 – Phenotypes of asthma and COPD Year: 2020
The impact of targeted therapy in children with uncontrolled allergic persistent severe asthma and nasal polyps Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities Year: 2017
The association between allergic rhinitis and sleep disorders in the French population Source: Eur Respir J 2003; 22: Suppl. 45, 116s Year: 2003
Dupilumab improves all ACQ-5 individual items in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) and asthma: results from a phase 2a trial Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017
Treatment of nasal polyposis in aspirine sensitive asthma Source: Eur Respir J 2001; 18: Suppl. 33, 425s Year: 2001
Nasal polyposis and risk of the airway‘s inflammation development Source: Annual Congress 2008 - Risk factors for asthma versus asthma control Year: 2008
Peculiarities of cytokine concentration in patients with nasal polyposis and asthmatic triad Source: International Congress 2018 – Asthma, rhinitis and COPD: cells, mediators, biomarkers and genetics Year: 2018
Impact of biologic therapy in severe asthma with nasal polyps Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021
Nasal polyposis and asthma: the otorhinolaryngologist's view Source: Eur Respir Monogr 2017; 76: 87-104 Year: 2017
Type 2 inflammation-related comorbidities among patients with asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020
Patient characteristics and treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in Canada Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough Year: 2021